Business Context and Reporting Period
Company: Genesis Biopharma, Inc. (Note: Request metadata listed "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text identifies the registrant as Genesis Biopharma, Inc., formerly Freight Management Corp.)
Reporting Period: Quarterly period ended September 30, 2010.
Status: Development stage biopharmaceutical company. The company has no revenue-generating operations to date and is focused on the development of an anti-CD55 antibody therapy for cancer and infectious diseases. The company is classified as a "smaller reporting company."
Key Financial Metrics
| Metric | Value (Nine Months Ended Sep 30, 2010) | Value (Nine Months Ended Sep 30, 2009) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(866,066) | $(13,427) |
| Operating Expenses | $319,336 | $13,427 |
| Cash and Cash Equivalents (Sep 30, 2010) | $795,943 | $618 (Sep 30, 2009) |
| Total Assets | $1,020,235 | $9,632 (Dec 31, 2009) |
| Total Liabilities | $572,222 | $23,120 (Dec 31, 2009) |
| Derivative Liability | $546,730 | $0 |
| Stockholders' Equity | $448,013 | $(13,488) (Dec 31, 2009) |
Liquidity: Net cash used in operating activities was $251,213 for the nine months ended September 30, 2010. Net cash provided by financing activities was $1,041,880, primarily from private placements.
Material Changes vs. Prior Period
- Operational Shift: In March 2010, the company completed a reverse merger with Genesis Biopharma, Inc., changing its name and business focus from freight management to biopharmaceuticals.
- Expense Surge: General and administrative expenses increased from $13,427 in the prior nine-month period to $319,336, driven by product development, marketing, and SEC filing costs.
- Derivative Liability: A significant non-cash charge of $563,348 was recorded for the fair value of derivative liabilities (warrants) issued in a September 2010 private placement. This was offset by a $16,618 gain from the change in fair value of these derivatives.
- Capitalization: The company raised approximately $1.065 million in gross proceeds through two private placements in 2010, significantly increasing cash reserves from $8,257 at the start of the year to $795,943.
- Intangible Assets: Acquired intellectual property licenses valued at $217,408, issued in exchange for common stock.
Outlook, Risks, and Management Commentary
- Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses and negative cash flows since inception.
- Capital Needs: Management estimates current cash resources will sustain operations for approximately six months. Additional financing (debt or equity) is required to develop products and fund an investor relations campaign.
- Revenue Outlook: The company does not expect to generate significant revenue in the foreseeable future. It is in the early research stage, and product development will take significant time.
- Risks: Risks include the inability to secure additional financing, potential dilution of shareholders from future equity sales, and the uncertainty of clinical development success.
- Subsequent Event: On October 22, 2010, the company closed a private placement for $250,000, which triggered anti-dilution provisions on previously issued warrants, reducing their exercise price.
Investor Verification Checklist
- Capital Runway: Verify the company's ability to raise the necessary capital within the next six months to avoid insolvency.
- Derivative Liability Impact: Assess the potential for future volatility in the financial statements due to the re-measurement of the $546,730 derivative liability.
- Dilution Risk: Review the terms of outstanding warrants (933,348 shares) and options (1,150,000 shares) and the impact of anti-dilution provisions on future share counts.
- Intellectual Property: Confirm the status and validity of the acquired anti-CD55 antibody patents and the terms of the license agreement with Cancer Research Technology Limited.
- Management Changes: Note the complete turnover of executive leadership and the board of directors in March 2010.